PDB38 ADDITION OF INCRETIN-THERAPY TO METFORMIN IN TYPE-2DIABETES MELLITUS (T2DM)- COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS SITAGLIPTIN FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)72096-4
https://www.valueinhealthjournal.com/article/S1098-3015(11)72096-4/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
252
First Page :
A290
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72096-4&doi=10.1016/S1098-3015(11)72096-4